Jeff P. Sharman, MD, discusses the challenges of adjusting treatments based on minimal residual disease status in high-risk chronic lymphocytic leukemia.
Jeff P. Sharman, MD
Advertisement
Articles by Jeff P. Sharman, MD
Jeff P. Sharman, MD, discusses unmet clinical needs in the treatment of patients with high-risk relapsed/refractory chronic lymphocytic leukemia.
Jeff P. Sharman, MD, discusses the results of the phase 3 GENUINE trial in chronic lymphocytic leukemia.
Advertisement
Latest Updated Articles
Dr. Sharman on the Challenges of Adjusting Treatment Based on MRD Status in CLLPublished: June 26th 2020 | Updated:
Dr. Sharman on the Results of the GENUINE Trial in CLLPublished: June 5th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5